Longeveron (LGVN) Stock Forecast, Price Target & Predictions
LGVN Stock Forecast
Longeveron stock forecast is as follows: an average price target of $10.00 (represents a 434.76% upside from LGVN’s last price of $1.87) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LGVN Price Target
LGVN Analyst Ratings
Buy
Longeveron Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 29, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $3.44 | 190.70% | 434.76% |
10
Longeveron Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $10.00 |
Last Closing Price | $1.87 | $1.87 | $1.87 |
Upside/Downside | -100.00% | -100.00% | 434.76% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 27, 2024 | Maxim Group | Buy | Buy | Hold |
Jul 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
10
Longeveron Financial Forecast
Longeveron Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $150.00K | $217.00K | $279.00K | $121.00K | $265.00K | $466.00K | $370.00K | $209.00K |
Avg Forecast | $1.23M | $1.18M | $1.09M | $1.05M | $609.50K | $594.50K | $564.00K | $549.00K | $418.00K | $395.50K | $500.00K | $60.00K | $210.00K | $400.00K | $400.00K | $300.00K | $400.00K | $200.00K | $200.00K | $250.00K | $265.00K |
High Forecast | $1.42M | $1.37M | $1.27M | $1.21M | $706.08K | $688.70K | $653.37K | $635.99K | $441.88K | $458.17K | $579.23K | $69.51K | $290.00K | $463.38K | $463.38K | $347.54K | $463.38K | $200.00K | $200.00K | $250.00K | $265.00K |
Low Forecast | $982.83K | $946.85K | $874.07K | $837.29K | $487.42K | $475.42K | $451.03K | $439.04K | $382.17K | $316.28K | $399.85K | $47.98K | $130.00K | $319.88K | $319.88K | $239.91K | $319.88K | $200.00K | $200.00K | $250.00K | $265.00K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.54% | 0.93% | 0.30% | 1.32% | 2.33% | 1.48% | 0.79% |
Forecast
Longeveron EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.16M | $-5.71M | $-4.72M | $-4.56M | $-5.00M | $-4.00M | $-3.21M | $-8.46M |
Avg Forecast | $-960.77K | $-925.59K | $-854.45K | $-818.49K | $-476.48K | $-464.75K | $-440.91K | $-429.18K | $-326.77K | $-309.18K | $-390.88K | $-46.91K | $-164.17K | $-312.70K | $-312.70K | $-234.53K | $-312.70K | $-156.35K | $-156.35K | $-4.08M | $-207.16K |
High Forecast | $-768.33K | $-740.20K | $-683.31K | $-654.55K | $-381.04K | $-371.66K | $-352.59K | $-343.22K | $-298.76K | $-247.25K | $-312.58K | $-37.51K | $-101.63K | $-250.07K | $-250.07K | $-187.55K | $-250.07K | $-156.35K | $-156.35K | $-3.26M | $-207.16K |
Low Forecast | $-1.11M | $-1.07M | $-989.85K | $-948.19K | $-551.98K | $-538.39K | $-510.77K | $-497.19K | $-345.44K | $-358.17K | $-452.81K | $-54.34K | $-226.71K | $-362.25K | $-362.25K | $-271.69K | $-362.25K | $-156.35K | $-156.35K | $-4.89M | $-207.16K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.50% | 18.27% | 20.11% | 14.57% | 32.01% | 25.56% | 0.79% | 40.85% |
Forecast
Longeveron Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.90M | $-5.63M | $-4.58M | $-3.77M | $-5.30M | $-7.03M | $-3.63M | $-8.92M |
Avg Forecast | - | - | - | - | $-3.82M | $-3.95M | $-4.91M | $-5.18M | $-4.84M | $-5.31M | $-15.26M | $-27.32M | $-29.07M | $-30.66M | $-33.62M | $-29.07M | $-27.26M | $-14.32M | $-14.76M | $-4.31M | $-16.27M |
High Forecast | - | - | - | - | $-2.82M | $-2.92M | $-3.63M | $-3.94M | $-4.52M | $-3.93M | $-11.29M | $-20.21M | $-26.30M | $-22.68M | $-24.86M | $-21.50M | $-20.16M | $-14.32M | $-14.76M | $-3.45M | $-16.27M |
Low Forecast | - | - | - | - | $-4.60M | $-4.77M | $-5.92M | $-6.32M | $-5.16M | $-6.41M | $-18.41M | $-32.95M | $-31.84M | $-36.98M | $-40.54M | $-35.06M | $-32.87M | $-14.32M | $-14.76M | $-5.17M | $-16.27M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.19% | 0.17% | 0.16% | 0.14% | 0.37% | 0.48% | 0.84% | 0.55% |
Forecast
Longeveron SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.37M | $3.52M | $2.01M | $1.92M | $2.32M | $2.66M | $2.27M | $5.39M |
Avg Forecast | $8.39M | $8.08M | $7.46M | $7.15M | $4.16M | $4.06M | $3.85M | $3.75M | $2.85M | $2.70M | $3.41M | $409.46K | $1.43M | $2.73M | $2.73M | $2.05M | $2.73M | $1.36M | $1.36M | $1.71M | $1.81M |
High Forecast | $9.72M | $9.36M | $8.64M | $8.28M | $4.82M | $4.70M | $4.46M | $4.34M | $3.02M | $3.13M | $3.95M | $474.34K | $1.98M | $3.16M | $3.16M | $2.37M | $3.16M | $1.36M | $1.36M | $1.71M | $1.81M |
Low Forecast | $6.71M | $6.46M | $5.96M | $5.71M | $3.33M | $3.24M | $3.08M | $3.00M | $2.61M | $2.16M | $2.73M | $327.44K | $887.16K | $2.18M | $2.18M | $1.64M | $2.18M | $1.36M | $1.36M | $1.71M | $1.81M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.24% | 1.29% | 0.98% | 0.70% | 1.70% | 1.95% | 1.33% | 2.98% |
Forecast
Longeveron EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.27 | $-0.22 | $-0.18 | $-0.25 | $-0.34 | $-0.17 | $-0.45 |
Avg Forecast | - | - | - | - | $-0.28 | $-0.29 | $-0.36 | $-0.38 | $-0.35 | $-0.39 | $-1.12 | $-2.00 | $-2.13 | $-2.25 | $-2.47 | $-2.13 | $-2.00 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
High Forecast | - | - | - | - | $-0.21 | $-0.21 | $-0.27 | $-0.29 | $-0.33 | $-0.29 | $-0.83 | $-1.48 | $-1.93 | $-1.66 | $-1.82 | $-1.58 | $-1.48 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Low Forecast | - | - | - | - | $-0.34 | $-0.35 | $-0.43 | $-0.46 | $-0.38 | $-0.47 | $-1.35 | $-2.42 | $-2.34 | $-2.71 | $-2.97 | $-2.57 | $-2.41 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.11% | 0.10% | 0.09% | 0.11% | 0.15% | 0.08% | 0.18% |
Forecast
Longeveron Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
KPRX | Kiora Pharmaceuticals | $3.31 | $120.00 | 3525.38% | Buy |
BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
LGVN | Longeveron | $1.87 | $10.00 | 434.76% | Buy |
CCCC | C4 Therapeutics | $4.01 | $13.50 | 236.66% | Buy |
LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
ERAS | Erasca | $2.60 | $6.50 | 150.00% | Buy |
KZR | Kezar Life Sciences | $7.62 | $17.50 | 129.66% | Buy |
KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |